Company Overview

Autonomix Medical, Inc. is a clinical-stage medical device company focused on developing technologies for the diagnosis and treatment of disorders involving the peripheral nervous system. The company operates within the medical technology and interventional healthcare industries, with a primary emphasis on conditions driven by nerve-related pain and dysfunction. Autonomix Medical does not currently generate material commercial revenue and remains focused on research, development, and clinical validation.

The company’s core product is a proprietary catheter-based microchip sensing and ablation platform designed to identify and selectively treat problematic nerve signals while minimizing damage to surrounding tissue. Its initial clinical focus has been on chronic pain indications, including pain associated with pancreatic cancer. Autonomix Medical traces its origins to earlier neurotechnology research and was later restructured and publicly listed as Autonomix Medical, Inc., trading on the Nasdaq under the ticker AMIX following a business combination that positioned it as a standalone medical device developer.

Business Operations

Autonomix Medical’s operations are centered on a single operating segment focused on the development of its nerve-sensing and ablation system, which integrates microchip-based signal detection with targeted energy delivery. The company’s activities primarily include device engineering, preclinical research, clinical trials, regulatory strategy, and intellectual property development rather than manufacturing at scale or commercial distribution.

Operations are primarily U.S.-based, with clinical and regulatory efforts aligned to U.S. Food and Drug Administration pathways. Autonomix Medical controls its core technology through internally developed intellectual property and relies on a combination of internal teams and external vendors for prototyping, testing, and limited manufacturing. As of the latest publicly available filings, the company does not report significant international operations, commercial partnerships, or revenue-generating subsidiaries.

Strategic Position & Investments

Strategically, Autonomix Medical is positioned as a highly specialized innovator in nerve-targeted intervention, aiming to differentiate itself through its ability to precisely detect and treat nerve activity rather than relying on anatomical landmarks alone. The company’s growth strategy is focused on advancing its lead system through clinical trials, expanding potential indications beyond its initial pain-related targets, and pursuing regulatory clearance or approval.

Investment activity has been primarily directed toward research and development, clinical studies, and strengthening the company’s patent portfolio. Autonomix Medical has not disclosed material acquisitions of operating companies and does not maintain a diversified investment portfolio. Its strategic value proposition is tied to emerging demand for minimally invasive, non-opioid pain management technologies, though broader commercial applicability remains subject to clinical and regulatory outcomes.

Geographic Footprint

Autonomix Medical is headquartered in the United States, with its principal executive offices located in Texas. The company’s operational footprint is concentrated domestically, reflecting its current stage of development and focus on U.S. regulatory and clinical pathways.

While the company identifies broader global markets for long-term commercialization, its international presence is currently limited. Any future expansion into Europe, Asia, or other regions would be contingent on regulatory approvals, strategic partnerships, and additional capital deployment. At present, international operational influence remains minimal based on publicly available disclosures.

Leadership & Governance

Autonomix Medical is led by an executive team with experience in medical devices, healthcare innovation, and public company management. The leadership emphasizes disciplined capital allocation, regulatory rigor, and the development of differentiated technology platforms aimed at addressing unmet clinical needs.

Key executives include:

• Steven G. Anderson – President and Chief Executive Officer
• Michael A. Zimmerman – Chief Financial Officer
• Brad Hauser – Chief Technology Officer
• David C. Knoll – Chief Operating Officer

The company is governed by a board of directors responsible for oversight of strategy, risk management, and compliance as required of a U.S.-listed public company. Leadership communications consistently emphasize long-term value creation through clinical validation and regulatory success rather than near-term commercialization.